PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations

May 28, 2020

Kellsye P Fabian1, Michelle R Padget1, Renee N. Donahue1, Kristen Solocinski1, Yvette Robbins1, Clint T. Allen2, John H. Lee3, Shahrooz Rabizadeh4,5, Patrick Soon-Shiong4,5, https://orcid.org/0000-0001-7932-4072Jeffrey Schlom1 and https://orcid.org/0000-0001-5282-3154James W Hodge1
Author affiliations

Read Full Article

Contact us at

+1-844-MY NK CELLS (+1-844-696-5235)

Visit Newsroom

How Can ImmunityBio Help You?

Solutions for Patients

Many cancer therapies, including radiation therapy, chemotherapy, CAR-T therapy, and B-cell immunotherapy, severely weaken the immune system—the human body’s most important natural disease-fighting weapon. But ImmunityBio creates targeted, personalized immunotherapies that are designed to strengthen the immune system and enable it to outsmart your disease.

Learn More

Opportunities for Trial Investigators

The broad therapeutic potential and demonstrated safety of ImmunityBio’s immune-enhancing IL-15 superagonist Anktiva (N-803), engineered NK-92® cell-based therapies, and our next-generation adenovirus-vectored anti-cancer vaccines make them appealing therapeutics for testing by trial investigators who want to make a contribution to clinical cancer research. Interested clinicians and other are encouraged to contact ImmunityBio to find out how they may support discovery of future cancer treatments.

Learn More

Tools for Research Scientists

Our NK-92® easy-to-maintain and highly cytotoxic natural killer cell line provides a versatile bioanalytical testing tool that can help researchers develop functional killing assays that are more consistent and reliable than donor blood and reporter gene assays.

Learn More

ImmunityBio is continuously pursuing new immunotherapies designed to attack disease by enhancing the patient’s immune system, not weakening it.

About Us